ArticleClinical and translational gastroenterology2026
Evaluation of Endoscopic Ultrasound Delays in the Diagnosis of Pancreatic Cancer in Older Adults in the United States.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPancreatic cancer is among the most aggressive malignancies, with a 5-year survival rate of 10%. Most patients present with advanced disease, limiting curative treatment options. Endoscopic ultrasound with fine-needle biopsy is the standard for diagnosis and staging. Although early access to endoscopic ultrasound (EUS) may enable timely systemic therapy and improve resectability, uncertainty remains regarding how delays to EUS affect surgical resection rates and overall survival, particularly in older adults. We aimed to identify factors associated with delayed EUS and to evaluate its impact on surgical resection and overall survival.
methodsUsing national Medicare claims (2011-2020), we conducted a retrospective cohort study of beneficiaries aged 66 years or older with newly diagnosed pancreatic cancer. The index date was the most recent claim for a pancreatic lesion or abnormal liver enzymes, serving as the indicator for EUS referral. Delay to EUS was defined as >30 days between the index date and the EUS procedure. Multivariable logistic regression identified sociodemographic and clinical factors associated with delayed EUS. Cox proportional hazards models estimated the associations between delayed EUS and 2 outcomes: (i) pancreatic surgical resection and (ii) all-cause mortality.
resultsAmong 2,843 patients, 586 (20.6%) experienced a delay in EUS, 774 (27.2%) underwent surgery, and 1,591 (56.0%) died. Black patients were more likely to experience delay (adjusted odds ratio 1.65, 95%CI 1.09-2.51), whereas those with more comorbidities were less likely (adjusted odds ratio 0.95, 95%CI 0.90-0.99). Delayed EUS was associated with a lower likelihood of surgery (hazard ratio [HR] 0.73, 95%CI 0.61-0.88) but lower mortality (HR 0.58, 95%CI 0.50-0.66). Mortality increased with older age (HR 1.43, 95%CI 1.27-1.61) and comorbidity (HR 1.04, 95%CI 1.02-1.07). DISCUSSION: Timely EUS was associated with higher surgical resection rates, suggesting earlier access to curative treatment. Lower mortality among patients with delayed EUS possibly reflects disease severity confounding rather than benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.